title: [Interleukin-2 (Ronkoleykin) in the first-line chemotherapy for B-cell non-Hodgkin lymphoma].
abstract: In this paper we present the results of a randomized prospective study, in which we examined the influence of rIL-2 ("Ronkoleykin ") on the effectiveness of the R-CHOP combination in the first-line treatment of patients with B-cell non-Hodgkin lymphomas. From March 2006 to December 2009, the study included 109 newly diagnosed patients. Standard R-CHOP was used in 59 patients, in 50 patients rIL-2 was added, injected subcutaneously in a dose of 1 million IU per day during each course in 1-5th days. It was found that the inclusion of rIL-2 in the R-CHOP regimen increased the effectiveness of the treatment of B-cell NHL with a high-risk of poor disease's course.
authors.forename: N V
authors.initials: NV
authors.lastname: Sachivko
authors.forename: É A
authors.initials: ÉA
authors.lastname: Zhavrid
authors.forename: E V
authors.initials: EV
authors.lastname: Baranov
authors.forename: O A
authors.initials: OA
authors.lastname: Kolenik
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D018570:Risk Assessment; D012307:Risk Factors; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007376:Interleukin-2; C571759:R-CHOP protocol; D011994:Recombinant Proteins; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone